Vericel Co. (NASDAQ:VCEL) Insider Sean C. Flynn Sells 1,474 Shares

Vericel Co. (NASDAQ:VCEL) insider Sean C. Flynn sold 1,474 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $45.84, for a total value of $67,568.16. Following the sale, the insider now owns 487 shares of the company’s stock, valued at $22,324.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vericel Trading Up 2.6 %

Shares of VCEL stock opened at $46.19 on Tuesday. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The company has a market capitalization of $2.24 billion, a PE ratio of -4,619.00 and a beta of 1.74. The firm has a fifty day simple moving average of $46.54 and a 200-day simple moving average of $44.30.

Vericel (NASDAQ:VCEL) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The company had revenue of $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. During the same period last year, the firm earned ($0.16) earnings per share. The company’s revenue was up 25.0% on a year-over-year basis. Equities research analysts predict that Vericel Co. will post 0.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VCEL. HC Wainwright boosted their price target on Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. TD Cowen began coverage on shares of Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 target price for the company. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Truist Financial reissued a “buy” rating and issued a $54.00 target price on shares of Vericel in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.17.

Institutional Investors Weigh In On Vericel

Institutional investors have recently modified their holdings of the stock. MCF Advisors LLC increased its holdings in Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 223 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new stake in shares of Vericel during the 1st quarter valued at approximately $27,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Vericel during the 4th quarter valued at approximately $33,000. GAMMA Investing LLC acquired a new position in Vericel in the fourth quarter worth $65,000. Finally, Lazard Asset Management LLC boosted its holdings in Vericel by 178.7% in the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 1,657 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.